MYOK MyoKardia Inc.

MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy

BRISBANE, Calif. and WASHINGTON, Nov. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (NASDAQ: MYOK), and the American College of Cardiology (ACC) announced the establishment of a nationwide registry of hypertrophic cardiomyopathy (HCM), which leverages the ACC’s PINNACLE Cardiovascular Registry operated by Veradigm®, an Allscripts (NASDAQ: MDRX), business unit. The registry will support MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, an investigational therapeutic for the treatment of obstructive hypertrophic cardiomyopathy (HCM).

The newly established mavacamten long-term safety registry will utilize the PINNACLE Registry, the largest out-patient cardiovascular registry in the U.S. The PINNACLE Registry was established in 2008 by the ACC and now includes more than 3,600 participating clinical practices, serving to capture and share outcomes data on cardiovascular conditions, including coronary artery disease, hypertension, heart failure and atrial fibrillation.

The DISCOVER (Deliver Insights on Safety in Hypertrophic Cardiomyopathy and ObserVe Endpoints in Real-world)-HCM study will evaluate the long-term safety and effectiveness of mavacamten based on real-world usage, for the treatment of patients with symptomatic, obstructive HCM. Veradigm will be conducting outreach to existing PINNACLE Registry sites, as well as additional HCM specialty treatment centers, for participation in DISCOVER-HCM to ensure that the population of the registry is broadly representative of HCM patients in the US. The DISCOVER-HCM study is expected to begin enrolling patients in the summer of 2021. The registry will also focus on gaining the patient perspective on the benefits of HCM treatments by using patient-focused technologies to learn whether registry participants are experiencing symptomatic changes in managing this serious, chronic illness. Additionally, this observational research effort will serve as the foundation for future global assessments of the benefit-risk of mavacamten in HCM with real-world use.

“Patients with hypertrophic cardiomyopathy have been waiting for a precision therapy like mavacamten,” said James Januzzi, M.D., Hutter Family Professor, Harvard Medical School; Cardiology, Massachusetts General Hospital; Trustee, American College of Cardiology and the DISCOVER-HCM Study Steering Committee Co-Chair.

“The DISCOVER-HCM study will provide crucial long-term safety and activity information about mavacamten, which should greatly add to our understanding of obstructive HCM. We are thrilled to be partnering with MyoKardia on this important effort,” added Adrian Hernandez, M.D., Professor, Vice Dean and Executive Director of Duke Clinical Research Institute and Steering Committee Co-Chair and the Principal Investigator for DISCOVER-HCM.

“As we look forward to the potential approval of mavacamten in the U.S., the establishment of an HCM registry will enable us to collect, analyze and track long-term safety data for our patients, expand our knowledge of the natural history of disease and compare outcomes among patients who are treated with mavacamten and those who are not,” said Jay Edelberg, M.D., Ph.D., MyoKardia’s Chief Medical Officer. “Collaborating with the ACC and Veradigm to utilize the PINNACLE Registry and recruit from the ACC’s vast and diverse network of professional cardiologists was a logical choice as we thought about creating a leading repository of real-world HCM data.”

“We look forward to working with MyoKardia and ACC to hit the ground running in recruiting sites for the prospective DISCOVER-HCM safety and effectiveness study of mavacamtem,” said Tom Langan, Chief Executive Officer of Veradigm.

HCM is a chronic, progressive disease in which excessive contraction of the heart muscle and reduced ability of the left ventricle to fill can lead to the development of debilitating symptoms and cardiac dysfunction. HCM is estimated to affect one in every 500 people. The most frequent cause of HCM is mutations in the heart muscle proteins of the sarcomere. In approximately two-thirds of individuals with HCM, the path followed by blood exiting the heart, known as the left ventricular outflow tract (LVOT), becomes obstructed by the enlarged and diseased muscle, restricting the flow of blood from the heart to the rest of the body (obstructive HCM). In other patients, the thickened heart muscle does not block the LVOT, and their disease is driven by diastolic impairment due to the enlarged and stiffened heart muscle (non-obstructive HCM). In individuals with either obstructive or non-obstructive HCM, exertion can result in fatigue or shortness of breath, interfering with a patient’s ability to participate in activities of daily living. HCM has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

Mavacamten is a potential first-in-class medicine developed to correct the abnormal function of the HCM heart targeting the cardiac muscle proteins with the aim of inhibiting the hypercontractility, left ventricular hypertrophy and reduced compliance that are characteristic of HCM. Earlier this year, MyoKardia published positive data from the pivotal 3 EXPLORER clinical trial of patients with symptomatic, obstructive HCM. Mavacamten has received orphan drug and breakthrough therapy designations from the U.S. Food and Drug Administration and MyoKardia plans to file a new Drug Application with the agency in the first quarter of 2021.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.

MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.

About American College of Cardiology

The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

About Veradigm®

Veradigm is an integrated data platforms and services business unit of Allscripts that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery. The company has a long-term strategic partnership with the American College of Cardiology (ACC), which includes the ownership and operation of the PINNACLE and Diabetes Collaborative patient registries. Veradigm works closely with ACC to provide innovative cardiovascular research solutions to Life Sciences companies. Veradigm’s mission is dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. To learn more, visit .

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates

Forward-Looking Statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the level of support the registry will provide to MyoKardia’s post-marketing safety and effectiveness study (DISCOVER-HCM) of mavacamten, expectations regarding the long-term safety and effectiveness of mavacamten based on real-world usage, for the treatment of patients with symptomatic, obstructive HCM, the timing and ability to ensure the right level of participation, of patients or sites, in DISCOVER-HCM to ensure that the population of the registry is broadly representative of HCM patients in the US, the likelihood that this observational research effort will serve as the foundation for future global assessments of the benefit-risk of mavacamten in HCM with real-world use or the likelihood of approval of mavacamten by the FDA reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information contact:

Contacts

Michelle Corral

Executive Director, Corporate Communications and Investor Relations

MyoKardia, Inc.

650-351-4690

Hannah Deresiewicz (investors)

Stern Investor Relations, Inc.

212-362-1200

Julie Normant (media)

W2O

628-213-3754

EN
11/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MyoKardia Inc.

Wedbush Research
  • Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
VIRC VIRCO MANUFACTURING CORP.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
FRX_CN FENNEC PHARMACEUTICALS
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
AMD ADVANCED MICRO DEVICES INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ETTX ENTASIS THERAPEUTICS HOLDINGS
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
TPTX TURNING POINT THERAPEUTICS
ISEE IVERIC BIO
PRVL PREVAIL THERAPEUTICS
KRTX KARUNA THERAPEUTICS INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
VIE VIELA BIO
IDYA IDEAYA BIOSCIENCES
FUSN FUSION PHARMACEUTICALS INC
KDNY CHINOOK THERAPEUTICS
BDTX INC.
ACET BLACK DIAMOND THERAPEUTICS
ITOS ADICET BIO INC
INZY ITEOS THERAPEUTICS
GBIO INOZYME PHARMA
GRAY GENERATION BIO
CYT GRAYBUG VISION
AVTE CYTEIR THERAPEUTICS
TCRR INC
CMPX AEROVATE THERAPEUTICS
INC.
TCR2 THERAPEUTICS INC
COMPASS THERAPEUTICS
Andreas Argyrides ... (+6)
  • Andreas Argyrides
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
FRX_CN FENNEC PHARMACEUTICALS
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ETTX ENTASIS THERAPEUTICS HOLDINGS
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
TPTX TURNING POINT THERAPEUTICS
ISEE IVERIC BIO
PRVL PREVAIL THERAPEUTICS
KRTX KARUNA THERAPEUTICS INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
VIE VIELA BIO
IDYA IDEAYA BIOSCIENCES
FUSN FUSION PHARMACEUTICALS INC
KDNY CHINOOK THERAPEUTICS
BDTX INC.
ACET BLACK DIAMOND THERAPEUTICS
ITOS ADICET BIO INC
INZY ITEOS THERAPEUTICS
CYT INOZYME PHARMA
AVTE CYTEIR THERAPEUTICS
TCRR INC
AEROVATE THERAPEUTICS
INC.
TCR2 THERAPEUTICS INC
Wedbush Research
  • Wedbush Research
2454 MEDIATEK CORPORATION
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
BLUE BLUEBIRD BIO INC.
XOMA XOMA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
VRNT VERINT SYSTEMS INC.
TSLA TESLA INC
STX SEAGATE TECHNOLOGY PLC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MU MICRON TECHNOLOGY INC.
MGNX MACROGENICS INC.
MFA MFA FINANCIAL INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
INTC INTEL CORPORATION
ICPT INTERCEPT PHARMACEUTICALS INC.
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FBC FLAGSTAR BANCORP INC.
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
EPZM EPIZYME INC.
EIGR EIGER BIOPHARMACEUTICALS
EBAY EBAY INC.
CYBR CYBERARK SOFTWARE LTD.
CTMX CYTOMX THERAPEUTICS INC.
CHMI CHERRY HILL MORTGAGE INVESTMENT
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
A117ME ALIBABA GROUP HOLDING LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALXN ALEXION PHARMACEUTICALS INC.
AGTC APPLIED GENETIC TECHNOLOGIES
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
MRVL MARVELL TECHNOLOGY GROUP LTD.
WD WALKER & DUNLOP INC.
SWKS SKYWORKS SOLUTIONS INC.
FRX_CN FENNEC PHARMACEUTICALS
5425 TAIWAN SEMICONDUCTOR CO. LTD.
HPE HEWLETT PACKARD ENTERPRISE CO.
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
ALBO ALBIREO PHARMA
CRVS CORVUS PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
VRNA VERONA PHARMA ADS
ANGI ANGI INC. CLASS A
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
ZS ZSCALER INC.
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
MGTA MAGENTA THERAPEUTICS
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
RGLS REGULUS THERAPEUTICS
COOP MR. COOPER GROUP INC.
TCRR TCR2 THERAPEUTICS
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
ORTX ORCHARD RX ADS
PINS PINTEREST INC. CLASS A
HARP HARPOON THERAPEUTICS
TPTX TURNING POINT THERAPEUTICS
ISEE IVERIC BIO
IMUX IMMUNIC INC
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
BCEL ATRECA
PRVL PREVAIL THERAPEUTICS
MLND MILLENDO THERAPEUTICS
DELL DELL TECHNOLOGIES INC CLASS C
KRTX KARUNA THERAPEUTICS INC.
STOK STOKE THERAPEUTICS
AXLA AXCELLA HEALTH
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
VIE VIELA BIO
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
BDTX BLACK DIAMOND THERAPEUTICS
FUSN INC.
NKLA FUSION PHARMACEUTICALS INC
U NIKOLA CORP.
PFSI UNITY SOFTWARE INC.
ACET PENNYMAC FINANCIAL SERVICES INC.
GRAY ADICET BIO
PASG INC
IAC GRAYBUG VISION
MTCH INC
FRLN PASSAGE BIO
ITOS IAC/INTERACTIVECORP.
INZY MATCH GROUP INC.
CDAK FREELINE THERAPEUTICS HOLDINGS ADS
ZNTL ITEOS THERAPEUTICS
BEAM INOZYME PHARMA
GBIO CODIAK BIOSCIENCES
PRAX INC.
FHTX ZENTALIS PHARMACEUTICALS
FUBO BEAM THERAPEUTICS
TVTX GENERATION BIO
RKT PRAXIS PRECISION MEDICINES
KNTE FOGHORN THERAPEUTICS
ABNB INC.
UWMC FUBOTV
CGNT TRAVERE THERAPEUTICS INC
ROCKET COMPANIES
KINNATE BIOPHARMA
AIRBNB INC. CLASS A
UNITED WHOLESALE MORTGAGE
COGNYTE SOFTWARE LTD.
Andreas Argyrides ... (+9)
  • Andreas Argyrides
  • Ashiq Mubarack
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
CTMX CYTOMX THERAPEUTICS INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ALXN ALEXION PHARMACEUTICALS INC.
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
FRX_CN FENNEC PHARMACEUTICALS
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
TCRR TCR2 THERAPEUTICS
HARP HARPOON THERAPEUTICS
BCEL ATRECA
PRVL PREVAIL THERAPEUTICS
KRTX KARUNA THERAPEUTICS INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
VIE VIELA BIO
AQST AQUESTIVE THERAPEUTICS
FUSN FUSION PHARMACEUTICALS INC
Wedbush Research
  • Wedbush Research
MA MASTERCARD INCORPORATED
GPN GLOBAL PAYMENTS INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WIX WIX.COM LTD.
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
V VISA INC. CLASS A
TSLA TESLA INC
STX SEAGATE TECHNOLOGY PLC
SQ SQUARE INC. CLASS A
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PYPL PAYPAL HOLDINGS INC
PSTG PURE STORAGE INC. CLASS A
PRTK PARATEK PHARMACEUTICALS INC
PCRX PACIRA BIOSCIENCES INC.
OMER OMEROS CORPORATION
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MYOK MYOKARDIA INC.
MU MICRON TECHNOLOGY INC.
MGNX MACROGENICS INC.
LXRX LEXICON PHARMACEUTICALS INC.
KURA KURA ONCOLOGY INC.
KPTI KARYOPHARM THERAPEUTICS
ICPT INTERCEPT PHARMACEUTICALS INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
GBT GLOBAL BLOOD THERAPEUTICS INC
FPRX FIVE PRIME THERAPEUTICS INC.
FISV FISERV INC.
FIS FIDELITY NATIONAL INFORMATION SERVICES INC.
FATE FATE THERAPEUTICS INC
EPZM EPIZYME INC.
CTMX CYTOMX THERAPEUTICS INC.
CRM SALESFORCE.COM INC.
CDTX CIDARA THERAPEUTICS
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ALXN ALEXION PHARMACEUTICALS INC.
ACOR ACORDA THERAPEUTICS INC.
ABUS ARBUTUS BIOPHARMA CORP.
MRVL MARVELL TECHNOLOGY GROUP LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
ALPN ALPINE SELECT AG
ADS ALLIANCE DATA SYSTEMS CORPORATION
SYRS SYROS PHARMACEUTICALS
UTHR UNITED THERAPEUTICS CORPORATION
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
OBSN OBSEVA
KALA KALA PHARMACEUTICALS INC.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
BHVN BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
ALNA ALLENA PHARMACEUTICALS
ARGX ARGEN-X SE
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
SURF SURFACE ONCOLOGY
IDRA IDERA PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
APTX APTINYX
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
ETTX ENTASIS THERAPEUTICS HOLDINGS
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
AQST AQUESTIVE THERAPEUTICS
HARP INC.
TCRR HARPOON THERAPEUTICS
FENC TCR2 THERAPEUTICS
INTC FENNEC PHARMA
BCEL INTEL CORP
PRVL ATRECA
KRTX PREVAIL THERAPEUTICS
STOK KARUNA THERAPEUTICS INC.
IGMS STOKE THERAPEUTICS
SWTX IGM BIOSCIENCES
VIE SPRINGWORKS THERAPEUTICS
TCF VIELA BIO
FUSN TCF FINANCIAL CORP
SHOP FUSION PHARMACEUTICALS INC
SHOPIFY

ResearchPool Subscriptions

Get the most out of your insights

Get in touch